Mouse study links STING immune signaling to age-related bone loss

A study published October 15 in Advanced Science identifies an immune-signaling pathway that may help explain how aging bone marrow becomes less supportive of bone formation. Experiments in mice and laboratory cells linked STING activity in marrow macrophages to inflammation and metabolic changes that impair neighboring bone-forming cells.

The findings concern a consequential part of healthy aging: maintaining a skeleton resistant to fractures. They also introduce a complication for drug development. Reducing the pathway’s activity had different effects at different ages, suggesting that any future intervention would need to account for when and where it acts.

### A connection between three cell types

The researchers examined communication among bone marrow fat cells, macrophages and mesenchymal stem cells, which can develop into bone-forming cells. Macrophages are immune cells that help regulate the local tissue environment; STING participates in their response to biological threats and cellular stress.

In laboratory experiments described in Wiley’s accompanying research summary, fat cells isolated from older mice promoted STING activation when cultured with macrophages from young mice. The investigators identified soluble DPP4 released by marrow fat cells as a contributor to this response.

The study’s abstract describes a downstream connection involving CD38, an enzyme linked to NAD+ metabolism. Increased CD38 activity reduced the availability of NMN, a precursor used to make NAD+, in the surrounding environment. That shortage impaired the bone-forming capacity of neighboring mesenchymal stem cells.

Together, these experiments support a proposed chain connecting marrow fat accumulation, immune activation and diminished bone formation. Establishing that chain in experimental models gives researchers specific interactions to test, rather than treating all age-related inflammation as interchangeable.

### The effect depended on age

The investigators also studied mice with STING deficiency in the relevant immune-cell compartment. The published abstract describes detrimental effects during early bone development and maturation, followed by protection against age-related bone loss from middle age onward.

That distinction matters when interpreting STING as a possible treatment target. A pathway that contributes to damage in an aging tissue may still serve useful functions earlier in life. Genetic deficiency also differs from giving a medicine to an older individual, so the two approaches cannot be assumed to produce identical results.

The authors additionally reported that combining pharmacological STING inhibition with NMN supplementation attenuated bone loss in preclinical models. This was an experimental combination; the finding does not establish that NMN supplements alone prevent osteoporosis or that the combination is safe or effective in people.

### Bone preservation is not yet fracture prevention

The reported outcomes concern experimental bone loss and cellular bone-forming capacity. They do not demonstrate fewer fractures, preserved independence or longer healthy life in humans.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases describes osteoporosis as a disorder involving reduced bone density or mass, or changes in bone structure and strength, that increases fracture risk. It often remains unnoticed until a fracture occurs and affects both older women and men. Those clinical consequences explain why understanding skeletal aging matters, but they also set a higher bar than changing a molecular marker.

The next questions include whether the same cellular interactions materially drive human bone loss, whether they can be modified selectively, and whether benefits would outweigh the consequences of altering immune signaling. For now, the study supplies a mechanistic direction for osteoporosis research, with clinical effectiveness still untested.